Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Jul 07, 2022 10:02am
148 Views
Post# 34808055

RE:RE:Risk for further dilution?

RE:RE:Risk for further dilution?Thanks for the extended reply. However, my concern was not addressed.

I agree that PRC Partners does not know more about the financial terms than you and me.

Nevertheless, in the PRC so called analysis they are talking about the company being courtered by funds and institutions. It's not easy to buy a significant portion on the open market without affecting the share price. 

Because of PRC reckless information we don't the effects. Since management accept the meetings, both already executed and future, I would like to understand if management is willing to let them in by means of dilution.

Since you bring up a new CEO in your response - I don't like the PRC were given the information to inform the rest of the market. That should have been published in the quarterly shareholder letter from the CEO - that is well overdue now!
<< Previous
Bullboard Posts
Next >>